An elevated ratio of placental growth factor to soluble Fms-like tyrosine kinase-1 predicts adverse outcomes in patients with stable coronary artery disease

Internal Medicine

Volumn 52, Issue 10, 2013, Pages 1019-1027

  Matsumoto, Takaki ^a   Uemura, Shiro ^a   Takeda, Yukiji ^a   Matsui, Masaru ^a   Okada, Sadanori ^a   Nishida, Taku ^a   Soeda, Tsunenari ^a   Okayama, Satoshi ^a   Somekawa, Satoshi ^a   Ishigami, Ken Ichi ^a   Onoue, Kenji ^a   Kawata, Hiroyuki ^a   Kawakami, Rika ^a   Horii, Manabu ^a   Saito, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Placental growth factor; Prognosis; Soluble Flt 1; Stable coronary artery disease

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SMOKING;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CAUSE OF DEATH; COMORBIDITY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLASMA; PREGNANCY PROTEINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84877856633     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.9073     Document Type: Article

References (34)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126, 1999.
3. Libby P. Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
4. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39: 469-478, 2006.
5. Holm PW, Slart RH, Zeebregts CJ, Hillebrands JL, Tio RA. Atherosclerotic plaque development and instability: a dual role for VEGF. Ann Med 41: 257-264, 2009.
6. Yla-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49: 1015-1026, 2007.
7. Couffinhal T, Kearney M, Witzenbichler B, et al. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol 150: 1673-1685, 1997.
8. Inoue M, Itoh H, Ueda M, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 98: 2108-2116, 1998.
9. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 8: 831-840, 2002.
10. Onoue K, Uemura S, Takeda Y, et al. Reduction of circulating soluble fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis. Circulation 120: 2470-2477, 2009.
11. Onoue K, Uemura S, Takeda Y, et al. Usefulness of soluble fmslike tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction. Am J Cardiol 104: 1478-1483, 2009.
12. Takeda Y, Uemura S, Iwama H, et al. Treatment with recombinant placental growth factor (PlGF) enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction. Circ J 73: 1674-1682, 2009.
13. Khurana R, Moons L, Shafi S, et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 111: 2828-2836, 2005.
14. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 9: 225-230; discussion 231, 2006.
15. Iwama H, Uemura S, Naya N, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol 47: 1559-1567, 2006.
16. Hochholzer W, Reichlin T, Stelzig C, et al. Impact of soluble fmslike tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur Heart J 32: 326-335, 2011.
17. Lenderink T, Heeschen C, Fichtlscherer S, et al. Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol 47: 307-311, 2006.
18. Heeschen C, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 291: 435-441, 2004.
19. Oemrawsingh RM, Lenderink T, Akkerhuis KM, et al. Multimarker risk model containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary syndrome. Heart 97: 1061-1066, 2011.
20. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.
21. Bhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 304: 1350-1357, 2010.
22. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297: 1197-1206, 2007.
23. Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 359: 677-687, 2008.
24. Pfisterer ME, Zellweger MJ, Gersh BJ. Management of stable coronary artery disease. Lancet 375: 763-772, 2010.
25. Adini A, Kornaga T, Firoozbakht F, Benjamin LE. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 62: 2749-2752, 2002.
26. Taylor AP, Goldenberg DM. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 6: 524-531, 2007.
27. Viglietto G, Maglione D, Rambaldi M, et al. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11: 1569-1579, 1995.
28. Matsumoto K, Suzuki K, Koike H, et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 23: 4953-4958, 2003.
29. Nagaoka S, Yoshida T, Akiyoshi J, et al. The ratio of serum placenta growth factor to soluble vascular endothelial growth factor receptor-1 predicts the prognosis of hepatocellular carcinoma. Oncol Rep 23: 1647-1654, 2010.
30. Kodama Y, Kitta Y, Nakamura T, et al. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol 48: 43-50, 2006.
31. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated metaanalyses. BMJ 321: 199-204, 2000.
32. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 297: 169-176, 2007.
33. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113: 2335-2362, 2006.
34. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 123: 551--565, 2011.